Grail
Precio: 60.16Empresa y modelo de negocio
Grail is a healthcare company focused on early cancer detection through advanced genomic testing. Its core products include multi-cancer early detection tests that analyze blood samples to identify various types of cancer at an early stage. The company primarily generates revenue from the sale of these diagnostic tests, targeting both healthcare providers and patients. Grail operates in the diagnostics segment of the healthcare industry, emphasizing innovation in cancer screening technologies.
Perfil de inversión
The investment profile of Grail suggests it may be more suitable for value investors due to its current financial challenges and lack of dividends. The stock's volatility and recent performance indicate a higher risk, which may not appeal to growth-focused investors. A balanced approach could be considered, but the overall outlook leans towards caution.
Métricas fundamentales
- EPS (TTM) — ganancias por acción de los últimos 12 meses, $
- -10.37 Riesgo
- Ingresos QoQ — crecimiento trimestral de ingresos
- -6.4% ↓
- Sorpresa EPS
- 17.1% mejor de lo esperado
- Volatilidad 20d
- 4.9% estable
Seguir en portafolio
Gráfico de precio
| Fecha | Antes | Después | Razón |
|---|---|---|---|
| 2026-06-03 02:42 | Mantener | Vender | scenario_deterioration |
| 2026-06-01 02:39 | Vender | Mantener | Weak fundamentals and high volatility raise significant concerns. |
| 2026-05-08 15:27 | — | Vender | Weak fundamentals and high volatility raise significant concerns. |
| Fecha | Analista | Acción | Objetivo | Precio entonces |
|---|---|---|---|---|
| 2026-06-05 06:33 | Goldman Sachs | Actualizar | — → 60 | 66.55 |
| 2026-05-06 11:22 | Piper Sandler | Objetivo aumentado | 54 → 56 | 54.4 |
| 2026-05-06 10:47 | Robert W. Baird | Objetivo reducido | 82 → 70 | 54.4 |